COVID-19 and inhibitors of the renin-angiotensin-aldosterone system

Expert Rev Anti Infect Ther. 2021 Jul;19(7):815-816. doi: 10.1080/14787210.2021.1851197. Epub 2020 Nov 26.

Authors

Musaddique Hussain¹, Qaiser Jabeen¹, Fiaz-Ud-Din Ahmad¹, Kashif-Ur-Rehman¹, Mobeen Fatima¹, Saira Shaukat¹, Abdul Majeed², Muhammad Qasim Barkat³, Ximei Wu³

Affiliations

¹ Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
² Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Mulatn, Pakistan.
³ Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou City, China.

No abstract available

Keywords: Angiotensin-converting enzyme 2; Covid-19; SARS-CoV-2; angiotensin-receptor blockers; hypertension.

Publication types

Editorial

MeSH terms

Angiotensin Receptor Antagonists / administration & dosage*
Angiotensin Receptor Antagonists / adverse effects
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Angiotensin-Converting Enzyme Inhibitors / adverse effects
COVID-19 / physiopathology*
Humans
Renin-Angiotensin System / drug effects

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors

Grants and funding

This paper was not funded.